Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

eJHaem

article

Semira Sheikh¹  Sepideh Mokhtari²  Jeffrey A. Silverman³  Kayla Reid⁴  Rawan Faramand⁵  Marco L. Davila⁶  Norman Franke⁷  Frederick L. Locke⁶  Michael D. Jain⁶  Daniel Wong⁸  John G. Kuruvilla⁷ 

[1] Division of Medical Oncology and Hematology, University Health Network;Department of Neuro-Oncology, Moffitt Cancer Center;Department of Hematology, North York General Hospital;Department of Hematology, Moffitt Cancer Center;Department of Malignant Hematology, Moffitt Cancer Center;Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center;Division of Medical Oncology and Hematology, Princess Margaret Hospital;Department of Neurology, North York General Hospital

关键词: CAR T cell therapy;    ICANS;    neurotoxicity;    transverse myelitis;   

DOI  :  10.1002/jha2.286

来源: Wiley

【 摘 要 】

Chimeric antigen receptor (CAR) T cell therapy has transformed thecare of patients with relapsed/refractory large B cell lymphoma andis associated with unique toxicities, in particular cytokine releasesyndrome (CRS) and neurotoxicity/immune effector cell-associatedencephalopathy syndrome (ICANS) [1–3]. The pathophysiology of neurotoxicity with CAR T cell therapy is not well understood, and a spectrum of presentations is increasingly recognized. Here we report thecase of a patient who developed transverse myelitis after receivingCAR T cell therapy.

【 授权许可】

Unknown